Gall bladder/bile duct disease Acute pancreatitis and other pancreatic disorders have been reported, though the relationship to treatment is unclear Injection-site reactions Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Primary mechanism(s) of action Selectively binds and activates both GIP and GLP-1 receptors Example Tirzepatide (Mounjaro) Dosage Initial: 2.5 mg subcutaneous injection once weekly, titrated up to 5 mg weekly after 4 weeks If additional glycemic control is needed, dosage can be increased in 2.5 mg increments after at least 4 weeks on the current dosage
10.1681/ASN.2013020134 159
No prescription, medication, weight-loss result, or health outcome is guaranteed
Mndez-Snchez N, Daz-Orozco LE
Metabolism and fat-burning support typically build over 24 weeks, and the best results often show up with consistent use over 68 weeks
Q10: Melanotan 2 nasal spray vs injection - what's the difference